Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
132 hedge funds and large institutions have $1.1B invested in Aimmune Therapeutics in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 37 reducing their positions, and 33 closing their positions.
147% more call options, than puts
Call options by funds: $4.9M | Put options by funds: $1.98M
38% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less funds holding
Funds holding: 142 → 132 (-10)
10% less capital invested
Capital invested by funds: $1.21B → $1.1B (-$115M)
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
+$20.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.4M |
| 3 |
Bank of New York Mellon
New York
|
+$9.89M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$6.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$15.1M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$8.59M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$6.98M |
| 4 |
BlackRock
New York
|
-$6.71M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.61M |
AIMT Hedge Fund Activity: Q4 2018 in Review
132 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2018, worth a combined $1.1B — down 9.5% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of AIMT and 23 opened new positions — a net loss of 10 holders — while 37 trimmed existing stakes and 51 added.
The largest buyer was Southpoint Capital Advisors, opening a new position worth an estimated $20.7M. The largest seller was Deerfield Management, exiting entirely with an estimated $15.1M sold.
- 132 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2018, down from 142 in Q3 2018.
- Funds reported $1.1B of Aimmune Therapeutics stock for Q4 2018, down 9.5% quarter-over-quarter.
- 23 funds opened new Aimmune Therapeutics positions in Q4 2018 and 33 closed out, a net change of -10 holders.
- The largest Aimmune Therapeutics buyer in Q4 2018 was Southpoint Capital Advisors, an estimated $20.7M added.
- The largest Aimmune Therapeutics seller in Q4 2018 was Deerfield Management, an estimated $15.1M sold.
Based on aggregated 13F filings for Q4 2018.